Connection
David Camidge to Focal Adhesion Protein-Tyrosine Kinases
This is a "connection" page, showing publications David Camidge has written about Focal Adhesion Protein-Tyrosine Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.042 |
|
|
|
-
Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020 01; 139:60-67.
Score: 0.042